Ozmosi | Luseogliflozin Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Luseogliflozin

Alternative Names: luseogliflozin, TS-071, TS071, TS 071
Clinical Status: Active
Latest Update: 2024-06-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: SGLT2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Japan | Malaysia | Philippines

Approved Indications: None

Known Adverse Events: None

Company: Taisho
Company Location: TOKYO M0 170-8655
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Luseogliflozin

Countries in Clinic: Japan

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Type 2 Diabetes

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

jRCT2031200244

jRCT2031200244

P3

Recruiting

Type 2 Diabetes

2025-03-31